Sarah Cannon And Healthone Announce Launch Of New Cancer Research Program

Top Quote Partnership between HealthONE and Sarah Cannon Cancer Network of Excellence expands access to early-phase cancer clinical trials in the Rocky Mountain region. End Quote
  • Denver, CO (1888PressRelease) February 19, 2015 - Today, the HealthONE Family of Hospitals and Sarah Cannon announced the opening of Sarah Cannon Research Institute (SCRI) at HealthONE, a cancer research program dedicated to conducting innovative clinical trials in a community setting. Located at 1800 Williams St. in Denver, near Presbyterian/St. Luke's Medical Center, the program offers patients access to the newest targeted cancer treatments.

    SCRI at HealthONE is led by Dr. Gerald Falchook, who has an extensive background in early-phase cancer research and has served as an investigator on more than 160 cancer clinical studies in his prior leadership position at MD Anderson Cancer Center. SCRI at HealthONE is a part of Sarah Cannon Research Institute, a network that has more than 20 years of experience conducting community-based clinical trials, including more than 150 first-in-man studies to date.

    "The opening of this program and appointment of Dr. Falchook marks an important step in our initiative to bring additional early-phase investigational treatments to patients in Denver and our region," said Sylvia Young, President and CEO, HealthONE. "Combining our deep clinical trial experience with SCRI's world-renowned cancer research will bolster our capabilities to deliver the most advanced and personalized care."

    The program offers clinical trials to patients in Colorado, as well as qualifying patients throughout the country and world, making it a destination for key cancer services. The SCRI at HealthONE facility offers a clinic, investigational pharmacy, lab space and an infusion center.

    "Through SCRI at HealthONE, we are able to give patients access to the most promising new treatments available for investigation, together with a supportive team of nurses, pharmacists, and lab personnel. In addition, our alignment with Sarah Cannon connects us to a global network of more than 1,000 oncologists engaged in clinical research." said Dr. Falchook.

    As previously announced in January of 2014, Sarah Cannon and HealthONE are partners to enhance clinical cancer programs by expanding patient access to care and clinical trials throughout the HealthONE family of hospitals. Sarah Cannon Research Institute is the research arm of the Sarah Cannon Cancer Network of Excellence, and has been a clinical trial leader in approximately 80 percent of the cancer therapies approved in the last three years.

    For more information about SCRI at HealthONE please visit

    About HealthONE
    HealthONE is the largest healthcare system in the metro Denver area with more than 10,000 employees.  As part of the HealthONE family, The Medical Center of Aurora, North Suburban Medical Center, Presbyterian/St. Luke's Medical Center, Rocky Mountain Hospital for Children, Rose Medical Center, Sky Ridge Medical Center, Swedish Medical Center, and Spalding Rehabilitation Hospital work together to provide a higher level of care.  In addition, our family of services includes five hospital affiliated free-standing emergency departments and numerous ambulatory surgery centers, occupational medicine & rehabilitation clinics, physician practices, radiation oncology centers, and AIRLIFE-DENVER, which provides critical care air and ground transportation across a 10-state region.

    About Sarah Cannon Research Institute
    Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the world's leading clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 1,000 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors and strategic investigator sites. 

  • FB Icon Twitter Icon In-Icon
Contact Information